CCHT(SZ:000661) Xin Lang Cai Jing·2025-09-17 11:27Core Viewpoint - Changchun High-tech announced a collaboration between its subsidiary Jinsai Pharmaceutical and Denmark's ALK-Abelló A/S for the development and commercialization of allergen-specific immunotherapy (AIT) products in China, specifically targeting house dust mites (HDM) [1] Group 1: Partnership Details - Jinsai Pharmaceutical will jointly develop and commercialize ALK's HDM allergen-specific immunotherapy products in China [1] - Jinsai Pharmaceutical has secured exclusive agency rights for three products independently developed by ALK within mainland China [1] Group 2: Financial Terms - An initial payment of €32.7 million will be made by Jinsai Pharmaceutical [1] - Jinsai Pharmaceutical will pay a milestone payment of €40 million upon regulatory approval for clinical trials of the ACARIZAX sublingual tablet for adults, adolescents, and children in China [1] - Future sales performance of the products in the Chinese market may lead to additional milestone payments of €105 million [1]